2018 Korean Liver Cancer Association and National Cancer Center for Clinical Practice Guidelines of Hepatocellular Carcinoma: What's Different from 2014?
10.4166/kjg.2019.74.2.101
- Author:
Ji Hoon KIM
1
Author Information
1. Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea. kjhhepar@naver.com
- Publication Type:Brief Communication
- Keywords:
Carcinoma, hepatocellular;
Guideline;
Therapeutics
- MeSH:
Carcinoma, Hepatocellular;
Continental Population Groups;
Humans;
Korea;
Liver Neoplasms;
Liver
- From:The Korean Journal of Gastroenterology
2019;74(2):101-109
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The Korean clinical practice guidelines for the management of hepatocellular carcinoma (HCC) was originally enacted in 2004 by the Korean Liver Cancer Association (KLCA)-National Cancer Center (NCC) Korea in order to provide medical practitioners with specific medical information regarding HCC to help them facilitate their understanding of the disease and treatment of the patients. KLCA-NCC Korea practice guidelines for the management of HCC have been revised entirely two times in 2009, and 2014. Although several major international liver association have established and revised clinical practice guidelines, since the medical environment in each country is somewhat different depending on race, region, institution, and economic conditions, it is necessary to revise the Korean guidelines to that reflect our medical environments and own research results. In this review, major change and its background will be summarized about 2018 updated clinical practice guidelines for the management of HCC.
